CONDUIT vs. PEEK Cages
Launched by UNIVERSITY OF PENNSYLVANIA · Mar 24, 2025
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Direct lateral interbody fusion (DLIF) is a powerful surgical tool in a spine surgeon's armamentarium to address lumbar spine pathology minimally invasively. It has been widely adopted amongst spine surgeons to gain access to the lumbar disc through a small incision on a patient's flank. Through a retroperitoneal approach, the surgeon can perform discectomy, prep end plates, and insert an interbody cage with a much longer (lateral-medial) and wider (anterior-posterior) footprint than posterior lumbar interbody fusion (PLIF). Using either transpsoas or anterior-to-psoas (ATP) technique, the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patients with one to two consecutive level lumbar degenerative disease from L2to S1, including Grade 1 (\<25%) Spondylolisthesis
- • Patients undergoing direct lateral interbody fusion (transpsoas or anterior-to-psoas approach) for lumbar disease
- • Skeletally mature patients, aged 18 and older
- • Patients able to fully comply with the clinical protocol and adhere to the follow-up schedule and protocol requirements
- • Patients able to understand and sign the study-specific, IRB approved informed consent form
- Exclusion Criteria:
- • • Spondylolisthesis greater than Grade 1
- • Traumatic lumbar disease
- • Spinal Deformity
- • Coronal Cobb angle greater than 40 degrees
- • Severe sagittal imbalance
- • Existing fusion construct longer than 2 consecutive levels
- • Active infection - systemic or local
- • Tumor diagnosis
- • Untreated osteoporosis, defined as T Spine \< -2.5 on DEXA scan
- • Active smoking habit
- • Current incarceration
- • Pregnancy
- • Involvement in an active spinal litigation
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported